Celcuity Inc. (CELC) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

43/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

28

Expensive

Momentum

53

Neutral

Sentiment

70

Bullish

Risk resilience

53

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Brian F. Sullivan
Listed since: Sep 19, 2017
Employees: 155

Market position

Day range

Current $93.53

$91.14$95.40

52-week range

Current $93.53

$44.42$151.02

Open: $91.775
Previous close: $90.57
Volume: 889.3K; 0.64× average
Average volume: 1.4M; Average daily volume
Market cap: 4.56B USD
Beta: 0.16; Market reference 1
50-day average: $93.8732; -0.37% below average
200-day average: $105.56; -11.39% below average

Earnings

EPS beat rate: 64%; 7 beats, 4 misses, 0 met estimates
Average EPS surprise: +0.00%; 11 comparable reports
Latest EPS result: -1.44; Estimate -1.16 · Miss by 24.14%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

12 ratings

Strong buy00%

Buy12100%

Hold00%

Sell00%

Strong sell00%

CELC news

seekingalpha.comAug 14, 2026

Celcuity: REVTORPYK Is Now A Commercial Story

Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial investment, with…

Read source

benzinga.comAug 14, 2026

Celcuity Analysts Slash Their Forecasts After Q2 Loss

Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday.

Read source

seekingalpha.comAug 13, 2026

Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript

Read source

marketbeat.comAug 13, 2026

Celcuity Q2 Earnings Call Highlights

Celcuity NASDAQ: CELC said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026 following its recent…

Read source

globenewswire.comAug 13, 2026

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications,…

Read source

defenseworld.netAug 10, 2026

California State Teachers Retirement System Acquires 12,201 Shares of Celcuity, Inc. $CELC

California State Teachers Retirement System lifted its holdings in Celcuity, Inc. (NASDAQ: CELC) by 91.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The…

Read source